A debate on ‘Psilocybin Access Rights’ will be heard in the House of Commons in mid-May.

We aim to frame these psychedelic research challenges with 4 fundamental questions.

This supports a recommendation for a trial of ketamine before a trial of ECT for patients with MDE, though this recommendation is limited by the small size and number of existing trials

PAP has the potential to comprehensively treat all biopsychosocial–spiritual dimensions of caregiver distress.

Reviewing clinical trials over roughly the last 30 years that examine psilocybin and MDMA-assisted therapies, the authors found almost no reports of serious adverse reactions in study participants, including in older adults.

Overall, a majority of individuals reported a willingness to try MDMA-assisted therapy if it were determined to be an appropriate treatment for them (58.8%).

This study uses a potentially more efficient/cost-effective 1-to-1 (rather than the currently standard 2-to-1) therapist-to-patient ratio.

Fruitful paths toward stronger theoretical and empirical approaches in the study of psychedelic-induced mystical experiences.

Daily questionnaires showed credible evidence (>99% posterior probability) of improved ratings of creativity, connectedness, energy, happiness, irritability, and wellness

Research typically demonstrates moderate benefit of CBM in chronic pain management.

Suggestions are provided for protocol design, screening processes, space considerations, therapist team structure, group process, music, timeline, as well as potential issues and challenges.

Classic psychedelic experiences may exert a positive effect on the cultivation and maintenance of health-related behaviors such as regular meditation practice.

Psychedelic drugs have good safety profiles, but a recent systematic review concluded that adverse events in psychedelic trials are poorly defined and not systematically assessed.

These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.

the acute and persisting clinical improvements observed following psilocybin support further study of its potential in the treatment of major depression.